The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have witnessed the achievements of convincing clinical benefits that feature the significantly prolonged overall survival (OS) of patients suffering from advanced non-small cell lung cancer (NSCLC), according to reports recently. Sensitivity to immunotherapy is related to several biomarkers, such as PD-L1 expression, TMB level, MSI-H and MMR. However, a further investigation into the novel biomarkers of the prognosis on ICIs treatment is required. In addition, there is an urgent demand for the establishment of a systematic hazard model to assess the efficacy of ICIs therapy for advanced NSCLC patients.

Methods

In this study, the gene mutation and clinical data of NSCLC patients was obtained from the TCGA database, followed by th

SUBMITTER: Hu X 

PROVIDER: S-EPMC8496027 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature